Please use this identifier to cite or link to this item:
|Title:||Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: A meta-analysis||Authors:||Teo, Y.L.
Tyrosine kinase inhibitors
|Issue Date:||Apr-2013||Citation:||Teo, Y.L., Ho, H.K., Chan, A. (2013-04). Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: A meta-analysis. Cancer Treatment Reviews 39 (2) : 199-206. ScholarBank@NUS Repository. https://doi.org/10.1016/j.ctrv.2012.09.004||Abstract:||Introduction: Although existing evidence from clinical trials has demonstrated manifestation of hepatic adverse events (AEs) with the use of tyrosine kinase inhibitors (TKIs), overall risks have yet to be reported. Thus we conducted a meta-analysis to determine the risk of hepatotoxicity associated with the use of TKIs, by comparing the occurrence of hepatotoxicity of the TKI arms against that of comparison arms. Methods: A comprehensive literature search of randomized control trials involving TKIs was performed. Only randomized, double-blind and placebo-controlled phase 2 or phase 3 human trials were included. The included studies must involve the comparison of a TKI against placebo, or the comparison of TKI with chemotherapy agent against placebo with the same chemotherapy agent. Results: Twelve articles were included in the analysis. There was a significant overall increase in the odds of developing high-grade (grade 3 or above) hepatotoxicity with the use of TKIs compared to the control arms (Pooled OR 4.35, 95% CI 2.96-6.39). The odds of developing all-types all-grades (Pooled OR 2.42, 95% CI 1.52-3.85) and high-grade hepatotoxicity due to elevation in alanine transaminase (Pooled OR 5.22, 95% CI 2.88-9.46), aspartate transaminase (Pooled OR 6.15, 95% CI 3.09-12.25) and total bilirubin (Pooled OR 1.76, 95% CI 0.59-5.24) was higher with the use of TKI than compared to the controls. Discussion: This is the first meta-analysis to demonstrate a significantly increased risk of hepatic AEs associated with TKIs use. Clinicians should be aware of this risk and provide close monitoring in patients receiving these therapies. © 2012 Elsevier Ltd.||Source Title:||Cancer Treatment Reviews||URI:||http://scholarbank.nus.edu.sg/handle/10635/106702||ISSN:||03057372||DOI:||10.1016/j.ctrv.2012.09.004|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jun 12, 2021
WEB OF SCIENCETM
checked on Jun 12, 2021
checked on Jun 20, 2021
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.